GLP-1 Prior Authorization: A Prescriber’s Playbook

Last updated: September 2026

For most weight-management practices, the GLP-1 prior authorization is the single biggest bottleneck between a good clinical decision and a treated patient. Approvals hinge on documentation and payer criteria that are inconsistent, opaque, and easy to get wrong — and every denial means delay, rework, and a frustrated patient. This playbook lays out why GLP-1 PAs get denied, the documentation payers actually want, how step therapy and coverage criteria work, how to write an appeal that succeeds, and how to build a PA workflow that keeps approvals moving.

It operationalizes the coverage realities described in our complete prescriber’s guide to GLP-1 medications for weight management and pairs with our billing and coding guide. Two things changed in 2026 that belong in every practice’s playbook: Medicare opened a temporary coverage pathway for weight-management GLP-1s, and the major health plans committed to a set of prior authorization reforms with real dates attached.

Key Takeaways

Why GLP-1 PAs Get Denied

Most denials are predictable, which means most are preventable. Understanding the recurring reasons lets you head them off before submission rather than reacting afterward.

The usual causes are a patient who does not clearly meet the plan’s BMI threshold, or meets it but without it documented; missing documentation of a weight-related comorbidity when the BMI is in the 27–29.9 range; step therapy that has not been completed or recorded; incomplete or non-specific diagnosis coding; and simple administrative gaps like a missing form field. Several of these are the same factors that drive good patient selection and contraindication screening — the clinical work and the paperwork are answering the same questions, so capturing both at once costs almost nothing extra.

A separate and important category is the outright exclusion — many plans do not cover anti-obesity medications at all, in which case the “denial” is really a benefit design, and no amount of documentation will change it. Distinguishing a fixable denial from a hard exclusion early saves everyone time.

The Documentation Payers Look For

Approvals are won or lost on documentation, and payers look for a consistent set of elements. Assembling them upfront — ideally at the first visit — is the highest-leverage habit in the entire process.

The core elements are a qualifying BMI (commonly 30 or greater, or 27 or greater with at least one weight-related comorbidity), explicit documentation of any comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea, and a record of prior weight-management efforts — many plans require documented diet, exercise, or lifestyle intervention, sometimes over a defined period (U.S. National Library of Medicine, 2025). Include the specific obesity diagnosis and BMI codes, aligned with the coding practices in our billing guide, and note any previously tried medications. The goal is a chart that answers the payer’s criteria point by point before they have to ask.

Step Therapy and Coverage Criteria

Step therapy — the requirement to try preferred or lower-cost options before a plan covers the requested drug — is one of the most common hurdles. A plan may require documented trials of older anti-obesity agents, or of a preferred GLP-1 before a non-preferred one. That is worth knowing before you write the first prescription, because choosing between tirzepatide and semaglutide is partly a formulary question as well as a clinical one, and starting on the plan’s preferred agent can save a month of back-and-forth.

Commercial coverage has not loosened as the class has grown. In a June 2026 employer survey, 36% of employers covered GLP-1s for both diabetes and weight loss — unchanged from 2025 — while 60% covered them for diabetes only. Among employers who do cover them for weight loss, 79% apply utilization management, and of those, 95% require prior authorization and 33% require reauthorization for refills (International Foundation of Employee Benefit Plans, 2026). Plan for the PA as the default, not the exception.

Medicare: the GLP-1 Bridge demonstration

Medicare historically excluded drugs used solely for weight loss, and coverage pathways opened first where an agent carried an additional approved indication — semaglutide’s approval to reduce cardiovascular risk, based on the SELECT trial, created a route to coverage that pure weight-loss labeling did not (Lincoff et al., 2023). That is still true, and it is still the cleanest route when a patient qualifies.

What is new is the Medicare GLP-1 Bridge, a temporary CMS demonstration running from July 1, 2026 through December 31, 2027. It covers Foundayo® (orforglipron), Wegovy® injection and tablets, and the Zepbound® KwikPen® at a flat $50 copay per prescription, regardless of which Part D benefit phase the beneficiary is in. Eligibility runs through defined BMI and comorbidity pathways, and the prescriber submits a prior authorization attesting — under penalty of perjury — that the patient meets them (Centers for Medicare & Medicaid Services, 2026).

Two practical notes for prescribers: a provider does not need to be enrolled in Medicare to write the prescription or submit the Bridge prior authorization, and the diagnosis code and annotation are not required for the pharmacy claim to process (Centers for Medicare & Medicaid Services, 2026). Because the criteria differ by plan and change often, the practical move on every other payer is to pull the specific plan’s policy before submitting, so you are documenting to the actual rules rather than a general template.

Writing Effective Appeals

A denial is frequently the beginning, not the end. Many initially denied GLP-1 requests are approved on appeal when the submission is stronger and speaks directly to the denial reason.

An effective appeal starts by reading the denial closely to identify the exact basis, then addresses that basis specifically rather than resubmitting the same packet. A concise letter of medical necessity that maps the patient’s clinical picture to the plan’s own coverage criteria — qualifying BMI, documented comorbidities, failed prior efforts, and clinical rationale — is the backbone. When available, a peer-to-peer review lets the prescriber make the case directly to the plan’s reviewer, which can resolve borderline cases quickly. Persistence matters: a well-targeted appeal, supported by complete documentation and relevant guidelines, changes outcomes (American Medical Association, 2026).

What the 2026–2027 reforms change

Health plans covering roughly 270 million Americans have committed to a shared set of prior authorization changes, and two of them are worth building into your workflow now. As of January 1, 2026, a new plan honors an existing prior authorization for 90 days when a patient switches coverage mid-treatment — which means a January plan change no longer has to interrupt a titration schedule, provided someone in the practice knows to invoke it. Plans also committed to clearer, plain-language explanations of determinations, including how to appeal. By January 1, 2027, standardized electronic submission through FHIR-based APIs is to be in place, with at least 80% of fully documented electronic requests answered in real time (AHIP, 2026).

Building an Efficient PA Workflow

The practices that thrive with GLP-1 therapy are the ones that turn prior authorization from an ad-hoc scramble into a system. The workflow is more important than any single submission.

Build a standard PA checklist that captures every commonly required element, and gather that documentation at the first visit rather than after a denial. Designate a staff member or role to own submissions and track their status, so nothing stalls unnoticed. Keep plan-specific criteria on hand for the payers you see most, and set patient expectations about timelines from the start. This is the operational layer of building a medical weight loss program, and it is usually what separates a program that scales from one that stays stuck at the fax machine.

Finally, know the fallback. When a plan simply excludes coverage, manufacturer self-pay channels — LillyDirect for tirzepatide and orforglipron, NovoCare Pharmacy for semaglutide — now bring approved, brand-name products within reach of many patients at a fraction of list price, which keeps care moving without an approvable claim. A documented self-pay pathway is also the safest answer when patients ask about compounded semaglutide, since self-pay pricing on FDA-approved products has narrowed the gap that made compounding attractive in the first place. Building this kind of efficient, compliant operation is exactly what IAPAM’s GLP-1 prescribing CME certification is designed to support.

Frequently Asked Questions

Why was my GLP-1 prior authorization denied?

Common reasons include not clearly meeting or documenting the plan’s BMI threshold, a missing weight-related comorbidity for BMIs of 27 to 29.9, incomplete step therapy, non-specific diagnosis coding, or a plan that excludes anti-obesity medications entirely. The last is a benefit exclusion rather than a fixable denial, and identifying it early saves everyone time.

What documentation is needed for a GLP-1 prior authorization?

Typically a qualifying BMI (30 or higher, or 27 or higher with a comorbidity), explicit documentation of comorbidities, a record of prior diet, exercise or lifestyle efforts, the specific obesity and BMI diagnosis codes, and any previously tried medications. Gather all of it at the first visit rather than after a denial.

What is step therapy for GLP-1 medications?

Step therapy requires trying preferred or lower-cost options before the plan covers the requested drug — for example, documented trials of older anti-obesity agents, or of a preferred GLP-1 before a non-preferred one. Documenting those trials, including dates and why they failed, is often a prerequisite for approval.

Does Medicare cover GLP-1 medications for weight loss in 2026?

Partly. Medicare still excludes drugs used solely for weight loss under standard Part D rules, but a temporary CMS demonstration called the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and covers Foundayo®, Wegovy® injection and tablets, and the Zepbound® KwikPen® at a flat $50 copay for beneficiaries who meet its BMI and comorbidity criteria. Patients who qualify through an additional approved indication, such as cardiovascular risk reduction or sleep apnea, use ordinary Part D coverage instead.

How do I appeal a denied GLP-1 prior authorization?

Read the denial to identify the exact reason, then address it directly with a letter of medical necessity mapping the patient to the plan’s own criteria, and request a peer-to-peer review when available. Resubmitting the same packet rarely works; a stronger, targeted appeal often does.

How can a practice reduce GLP-1 PA denials?

Use a standard PA checklist, gather documentation at the first visit, assign one person to own and track submissions, keep plan-specific criteria on hand for your most common payers, and set patient expectations about timelines. Have manufacturer self-pay programs ready as a fallback for plans that exclude coverage outright.

Conclusion

Winning GLP-1 prior authorizations is less about any single submission and more about a repeatable system: anticipate the common denial reasons, document to the payer’s actual criteria upfront, satisfy step therapy, appeal denials with targeted letters and peer-to-peer reviews, and run it all through an organized workflow. The 2026 additions — a Medicare pathway that did not exist a year ago and a 90-day continuity rule most practices are not yet claiming — reward the practices paying attention. Those practices convert more clinical decisions into treated patients, and spend less time fighting paperwork.

For the coding side, see our billing and coding guide, and for the clinical foundation, our complete prescriber’s guide to GLP-1 medications. And to build an efficient, compliant prescribing operation end to end, IAPAM’s GLP-1 prescribing CME certification — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — provides the clinical and practice frameworks. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training for nurse practitioners.

Explore GLP-1 Certification Training →

References

Disclaimer: This article is for informational and educational purposes only and does not constitute legal, billing, or coverage advice. Payer criteria and coverage policies vary and change frequently; always verify the specific plan’s current requirements before submitting a prior authorization.